These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 38652676)

  • 21. A series of novel aryl-methanone derivatives as inhibitors of FMS-like tyrosine kinase 3 (FLT3) in FLT3-ITD-positive acute myeloid leukemia.
    Sellmer A; Pilsl B; Beyer M; Pongratz H; Wirth L; Elz S; Dove S; Henninger SJ; Spiekermann K; Polzer H; Klaeger S; Kuster B; Böhmer FD; Fiebig HH; Krämer OH; Mahboobi S
    Eur J Med Chem; 2020 May; 193():112232. PubMed ID: 32199135
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Incorporating FLT3 inhibitors into acute myeloid leukemia treatment regimens.
    Pratz K; Levis M
    Leuk Lymphoma; 2008 May; 49(5):852-63. PubMed ID: 18452067
    [TBL] [Abstract][Full Text] [Related]  

  • 23. FLT3 inhibitors for the treatment of acute myeloid leukemia.
    Wiernik PH
    Clin Adv Hematol Oncol; 2010 Jun; 8(6):429-36, 444. PubMed ID: 20733555
    [TBL] [Abstract][Full Text] [Related]  

  • 24. FLT3 Inhibition in Acute Myeloid Leukemia.
    Smith CC
    Clin Lymphoma Myeloma Leuk; 2020 Sep; 20 Suppl 1():S5-S6. PubMed ID: 32862867
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Midostaurin: A New Oral Agent Targeting FMS-Like Tyrosine Kinase 3-Mutant Acute Myeloid Leukemia.
    Stansfield LC; Pollyea DA
    Pharmacotherapy; 2017 Dec; 37(12):1586-1599. PubMed ID: 28976600
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Efficacy and Feasibility of Sorafenib as a Maintenance Agent After Allogeneic Hematopoietic Stem Cell Transplantation for Fms-like Tyrosine Kinase 3 Mutated Acute Myeloid Leukemia: An Update.
    Battipaglia G; Massoud R; Ahmed SO; Legrand O; El Cheikh J; Youniss R; Aljurf M; Mohty M; Bazarbachi A
    Clin Lymphoma Myeloma Leuk; 2019 Aug; 19(8):506-508. PubMed ID: 31122828
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Implications of FLT3 mutations in the therapy of acute myeloid leukemia.
    Mattison RJ; Ostler KR; Locke FL; Godley LA
    Rev Recent Clin Trials; 2007 May; 2(2):135-41. PubMed ID: 18473998
    [TBL] [Abstract][Full Text] [Related]  

  • 28. FLT3 Inhibitors for Treating Acute Myeloid Leukemia.
    Hassanein M; Almahayni MH; Ahmed SO; Gaballa S; El Fakih R
    Clin Lymphoma Myeloma Leuk; 2016 Oct; 16(10):543-549. PubMed ID: 27450971
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Discovery of imidazo[1,2-a]pyridine-thiophene derivatives as FLT3 and FLT3 mutants inhibitors for acute myeloid leukemia through structure-based optimization of an NEK2 inhibitor.
    Zhang L; Lakkaniga NR; Bharate JB; Mcconnell N; Wang X; Kharbanda A; Leung YK; Frett B; Shah NP; Li HY
    Eur J Med Chem; 2021 Dec; 225():113776. PubMed ID: 34479037
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Discovery of N-(4-(6-Acetamidopyrimidin-4-yloxy)phenyl)-2-(2-(trifluoromethyl)phenyl)acetamide (CHMFL-FLT3-335) as a Potent FMS-like Tyrosine Kinase 3 Internal Tandem Duplication (FLT3-ITD) Mutant Selective Inhibitor for Acute Myeloid Leukemia.
    Liang X; Wang B; Chen C; Wang A; Hu C; Zou F; Yu K; Liu Q; Li F; Hu Z; Lu T; Wang J; Wang L; Weisberg EL; Li L; Xia R; Wang W; Ren T; Ge J; Liu J; Liu Q
    J Med Chem; 2019 Jan; 62(2):875-892. PubMed ID: 30565931
    [TBL] [Abstract][Full Text] [Related]  

  • 31. FLT3 inhibition as therapy in acute myeloid leukemia: a record of trials and tribulations.
    Fathi AT; Chabner BA
    Oncologist; 2011; 16(8):1162-74. PubMed ID: 21765192
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Novel Therapeutics in Acute Myeloid Leukemia.
    DiNardo CD; Stone RM; Medeiros BC
    Am Soc Clin Oncol Educ Book; 2017; 37():495-503. PubMed ID: 28561688
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Recent advances in FLT3 inhibitors for acute myeloid leukemia.
    Tong L; Li X; Hu Y; Liu T
    Future Med Chem; 2020 May; 12(10):961-981. PubMed ID: 32314599
    [TBL] [Abstract][Full Text] [Related]  

  • 34. FLT3 inhibitors for acute myeloid leukemia: a review of their efficacy and mechanisms of resistance.
    Grunwald MR; Levis MJ
    Int J Hematol; 2013 Jun; 97(6):683-94. PubMed ID: 23613268
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Gilteritinib, a FLT3/AXL inhibitor, shows antileukemic activity in mouse models of FLT3 mutated acute myeloid leukemia.
    Mori M; Kaneko N; Ueno Y; Yamada M; Tanaka R; Saito R; Shimada I; Mori K; Kuromitsu S
    Invest New Drugs; 2017 Oct; 35(5):556-565. PubMed ID: 28516360
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Anti-leukemic Activity of AIU2008 in FLT3-ITD-positive Acute Myeloid Leukemia.
    Kim HJ; Ryu H; Choi HK; Song JY; Hwang SG; Ahn J
    Anticancer Res; 2021 Feb; 41(2):731-737. PubMed ID: 33517277
    [TBL] [Abstract][Full Text] [Related]  

  • 37. FLT3 Inhibitors in Acute Myeloid Leukemia: Current Status and Future Directions.
    Larrosa-Garcia M; Baer MR
    Mol Cancer Ther; 2017 Jun; 16(6):991-1001. PubMed ID: 28576946
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Advancing treatment of acute myeloid leukemia: the future of FLT3 inhibitors.
    Elshoury A; Przespolewski A; Baron J; Wang ES
    Expert Rev Anticancer Ther; 2019 Mar; 19(3):273-286. PubMed ID: 30681373
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Targeting FLT3 to treat leukemia.
    Konig H; Levis M
    Expert Opin Ther Targets; 2015 Jan; 19(1):37-54. PubMed ID: 25231999
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Targeting on glycosylation of mutant FLT3 in acute myeloid leukemia.
    Hu X; Chen F
    Hematology; 2019 Dec; 24(1):651-660. PubMed ID: 31533545
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.